Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Bibliographic Details
Title: Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
Authors: Maria H. Gilleece, Avichai Shimoni, Myriam Labopin, Stephen Robinson, Dietrich Beelen, Gerard Socié, Ali Unal, Arnold Ganser, Antonin Vitek, Henrik Sengeloev, Ibrahim Yakoub-Agha, Eleni Tholouli, Emmanuelle Polge, Mohamad Mohty, Arnon Nagler
Source: Blood Cancer Journal, Vol 11, Iss 5, Pp 1-9 (2021)
Publisher Information: Nature Publishing Group, 2021.
Publication Year: 2021
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation registry assessed HCT outcomes by declared MRD status in a cohort of 1042 adult patients with AML CR2 at HCT. Patients were transplanted 2006–2016 from human leukocyte antigen (HLA) matched siblings (n = 719) or HLA 10/10 matched unrelated donors (n = 293). Conditioning was myeloablative (n = 610) or reduced-intensity (n = 432) and 566 patients (54%) had in-vivo T cell depletion. At HCT, 749 patients (72%) were MRD negative (MRD NEG) and 293 (28%) were MRD positive (MRD POS). Time from diagnosis to HCT was longer in MRD NEG than MRD POS patients (18 vs. 16 months (P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2044-5385
Relation: https://doaj.org/toc/2044-5385
DOI: 10.1038/s41408-021-00479-3
Access URL: https://doaj.org/article/f5e02edff8c94fb5bcc244e0029aefdc
Accession Number: edsdoj.f5e02edff8c94fb5bcc244e0029aefdc
Database: Directory of Open Access Journals
More Details
ISSN:20445385
DOI:10.1038/s41408-021-00479-3
Published in:Blood Cancer Journal
Language:English